Review



targetmol bioactive compound library  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    TargetMol targetmol bioactive compound library
    Targetmol Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 107 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pm41866544-110-1-1
    Average 97 stars, based on 107 article reviews
    targetmol bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    other:

    Article Title: Cell Painting in activated cells illuminates phenotypic dark space and drug mechanisms of action
    Article Snippet: We obtained a library of 8,387 bioactive compounds (L4000-CUST, listed in Supplementary Data 1) from TargetMol.

    Article Title: P2Y12-oriented computational screening and functional validation identify antiplatelet compounds with antithrombotic activity.
    Article Snippet: AutoDock Vina10 was used to dock the compound into the protein pocket and choose the best docking pose for the next analysis.

    Article Title: MD2-IN-1 restores microglial lysosomal function and attenuates amyloid pathology through TREM2-associated signaling in 5×FAD mice.
    Article Snippet: Triggering receptor expressed on myeloid cells 2 (TREM2) is a central regulator of microglial adaptation during Alzheimer’s disease (AD), yet the development of small-molecule modulators associated with TREM2 signaling remains limited.. Here, through a consensus pharmacophore-guided virtual screening strategy, MD2-IN-1 was identified as a candidate small molecule associated with TREM2 signaling.. Biolayer interferometry and cellular thermal shift assays supported cellular target engagement related to TREM2 (KD= 13.85 μM).

    Positive Control:

    Article Title: A Multifunctional Electrospun Membrane for Full-Thickness Abdominal Wall Defect Repair.
    Article Snippet: Electrospun nanofiber membranes hold promise for abdominal wall repair due to their biomimetic architecture and tunable properties.. However, their porous structure often induces an elevated foreign body response (FBR) that impedes tissue integration and remodeling.. While previous strategies have employed ibuprofen (IBU) to mitigate inflammation, its nonselective cyclooxygenase (COX) inhibition and rapid systemic clearance limit local therapeutic efficacy.

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Membrane:

    Article Title: A Multifunctional Electrospun Membrane for Full-Thickness Abdominal Wall Defect Repair.
    Article Snippet: Electrospun nanofiber membranes hold promise for abdominal wall repair due to their biomimetic architecture and tunable properties.. However, their porous structure often induces an elevated foreign body response (FBR) that impedes tissue integration and remodeling.. While previous strategies have employed ibuprofen (IBU) to mitigate inflammation, its nonselective cyclooxygenase (COX) inhibition and rapid systemic clearance limit local therapeutic efficacy.

    Sterility:

    Article Title: A Multifunctional Electrospun Membrane for Full-Thickness Abdominal Wall Defect Repair.
    Article Snippet: Electrospun nanofiber membranes hold promise for abdominal wall repair due to their biomimetic architecture and tunable properties.. However, their porous structure often induces an elevated foreign body response (FBR) that impedes tissue integration and remodeling.. While previous strategies have employed ibuprofen (IBU) to mitigate inflammation, its nonselective cyclooxygenase (COX) inhibition and rapid systemic clearance limit local therapeutic efficacy.

    Molecular Weight:

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Solvent:

    Article Title: Use of pyrido[1,2-a]pyrimidone analogue
    Article Snippet: F12 Culture medium (purchased from Gibco, product number: 11765-054); (3) Test Article and Positive Control Article Test article: compound I; Positive control article: Cisplatin, molecular weight: 300.05; solvent: PBS (phosphate buffer saline); storage condition: 2-8° C.; supplier: Qilu Pharmaceutical. .. Positive control article: Alpelisib, molecular weight: 441.47; solvent: DMSO; supplier: Shanghai TOPSCIENCE Biochemical Technology Co., Ltd., CAS number: 1217486-61-7; 2. ..

    Drug discovery:

    Article Title: Targeting the CD4 + effector memory T cells re-expressing CD45RA suppressor galectin-7: a multi-omics-guided therapeutic strategy for idiopathic pulmonary fibrosis.
    Article Snippet: .. A library of approximately 20,000 bioactive compounds (TargetMol Bioactive Compound Library) was prepared using the LigPrep module (Schrödinger, LLC, New York, NY, 2021). ..

    Article Title: Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening
    Article Snippet: .. Preprocessing of the small-molecule library and virtual screening The commercially available TargetMol Bioactive Compound Library (L4000), containing 17,284 small molecules, was used in this study. ..

    Screening:

    Article Title: Discovery of tepotinib as a novel LY75-targeting small-molecule inhibitor with anti-tumor activity in ovarian cancer via virtual screening
    Article Snippet: .. Preprocessing of the small-molecule library and virtual screening The commercially available TargetMol Bioactive Compound Library (L4000), containing 17,284 small molecules, was used in this study. ..



    Similar Products

    97
    TargetMol targetmol bioactive compound library
    Targetmol Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pm42456852-186-14-14
    Average 97 stars, based on 1 article reviews
    targetmol bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    TargetMol targetmol l9500 bioactive library
    Targetmol L9500 Bioactive Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Target-Focused+Phenotypic+Screening+Library/pm42349121-33-6-6
    Average 94 stars, based on 1 article reviews
    targetmol l9500 bioactive library - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol targetmol bioactive compounds library
    Targetmol Bioactive Compounds Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compounds+Library+Max/pm41729167-42-14-18
    Average 94 stars, based on 1 article reviews
    targetmol bioactive compounds library - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    97
    TargetMol targetmol l4000 library
    Targetmol L4000 Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/10__1021_slash_jacsau__5c01622-40-26-26
    Average 97 stars, based on 1 article reviews
    targetmol l4000 library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    97
    TargetMol targetmol bioactive library
    Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
    Targetmol Bioactive Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pmc12964606-44-11-11
    Average 97 stars, based on 1 article reviews
    targetmol bioactive library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    Image Search Results


    Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

    Journal: Alzheimer's Research & Therapy

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen

    doi: 10.1186/s13195-026-01960-6

    Figure Lengend Snippet: Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

    Article Snippet: We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.

    Techniques: Activity Assay, Disruption, Concentration Assay, Control, Analysis